exhibit 10. 2 portions of this exhibit have been omitted and separately filed with the securities and exchange commission with a request for confidential treatment amended and restated non exclusive license agreement this agreement is made this 1st day of july, 2008 ( hereinafter “ the date of signature ” ) by and between cellectis, a french societe anonyme, registered under the registre de commerce et des societes de paris under n° b 428 859 052, having its registered office at 102 avenue gaston roussel – 93235 romainville, france, represented by its legal representative, mr. andre choulika, directeur general ( hereinafter “ cellectis ” ) and regeneron pharmaceuticals, inc., a company organized and existing under the laws of the state of new york, having a principal place of business at 777 old saw mill river road, tarrytown, ny 10591 u. s. a. ( united states of america ), represented by its legal representative, mr. stuart kolinski, senior vice president & general counsel ( hereinafter “ regeneron ” ). regeneron and cellectis hereinafter individually or collectively referred to as the party ( ies ). witnesseth whereas, cellectis is a biotechnology company specialized in rational genome engineering. cellectis controls and develops tools and methods to rewrite dna sequences in genomes of living organisms. with these technologies, cellectis develops therapeutic drugs, as well as industrial tools to develop animal models and to engineer protein producer strains, animals or plants ; whereas, cellectis has exclusive rights, including the right to grant sublicenses, from institut pasteur, a french foundation located at 25 rue du docteur roux – 75015 paris france, the owner of patents ( as defined below ), relating to a process for the specific replacement or insertion of a gene in the receiver genome by homologous recombination ; whereas, regeneron is a biopharmaceutical company that has developed technologies and know - how to generate genetically modified animals, and that discovers, develops, and commercializes therapeutic medicines for the treatment of serious medical conditions ; whereas, regeneron and cellectis, parties to a non - exclusive license agreement dated as of december 12, 2003 ( as the same has been amended, modified, and july 1, 2008 exhibit 10. 2 portions